CR20210305A - Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b] [1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa paar el tratamiento de la enfermedad de alzheimer - Google Patents
Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b] [1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa paar el tratamiento de la enfermedad de alzheimerInfo
- Publication number
- CR20210305A CR20210305A CR20210305A CR20210305A CR20210305A CR 20210305 A CR20210305 A CR 20210305A CR 20210305 A CR20210305 A CR 20210305A CR 20210305 A CR20210305 A CR 20210305A CR 20210305 A CR20210305 A CR 20210305A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- octan
- azabicyclo
- pyrrolo
- triazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4r,7e,9as)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 229940124648 γ-Secretase Modulator Drugs 0.000 title abstract 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- BDJWKDVEYUXIRO-UHFFFAOYSA-N triazol-2-amine Chemical class NN1N=CC=N1 BDJWKDVEYUXIRO-UHFFFAOYSA-N 0.000 abstract 2
- 208000018282 ACys amyloidosis Diseases 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 206010011878 Deafness Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 abstract 1
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 abstract 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 208000017004 dementia pugilistica Diseases 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000010370 hearing loss Effects 0.000 abstract 1
- 231100000888 hearing loss Toxicity 0.000 abstract 1
- 208000016354 hearing loss disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 208000012005 synaptopathy Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención proporciona derivados de 7-fenoxi-N-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5H-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados de la fórmula general (I) en donde R1, Ar, n y m son como se describen en la presente, composiciones que incluyen los compuestos, procesos de elaboración de los compuestos y los compuestos para su uso en los métodos de tratamiento médico. Los presentes compuestos son como moduladores de gamma-secretasa para el tratamiento de enfermedades asociadas al depósito de β-amiloide en el cerebro, tales como enfermedad de Alzheimer, angiopatía amiloide cerebral, sinaptopatía coclear, hipoacusia, hemorragia cerebral hereditaria con amiloidosis de tipo holandés (HCHWA-D), demencia multiinfarto, demencia pugilística y síndrome de Down. La presente descripción divulga la preparación de compuestos de ejemplo así como los datos farmacológicos de estos (por ejemplo, las páginas 54 a 74; los ejemplos 1 a 64; tabla). Un compuesto de ejemplo es, por ejemplo, (R)-7-(3,5-difluorofenoxi)-N-((1R,5S,8s)-3-(6-metoxipiridazin-4-il)-3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5Hpirrolo[1,2-b][1,2,4]triazol-2-amina (ejemplo 1).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18212199 | 2018-12-13 | ||
PCT/EP2019/084538 WO2020120521A1 (en) | 2018-12-13 | 2019-12-11 | 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase modulators for the treatment of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210305A true CR20210305A (es) | 2021-07-20 |
Family
ID=64665266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210305A CR20210305A (es) | 2018-12-13 | 2019-12-11 | Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b] [1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa paar el tratamiento de la enfermedad de alzheimer |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220056036A1 (es) |
EP (1) | EP3894411A1 (es) |
JP (1) | JP2022513466A (es) |
KR (1) | KR20210102900A (es) |
CN (2) | CN117946116A (es) |
AR (1) | AR116906A1 (es) |
AU (1) | AU2019395774A1 (es) |
BR (1) | BR112021009443A2 (es) |
CA (1) | CA3117870A1 (es) |
CL (1) | CL2021001547A1 (es) |
CO (1) | CO2021006837A2 (es) |
CR (1) | CR20210305A (es) |
IL (2) | IL310081A (es) |
MA (1) | MA54447A (es) |
MX (1) | MX2021006761A (es) |
PE (1) | PE20211776A1 (es) |
SG (1) | SG11202103340PA (es) |
TW (1) | TWI831892B (es) |
WO (1) | WO2020120521A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8703763B2 (en) * | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
EP3347363B1 (en) * | 2015-09-09 | 2020-01-01 | H. Hoffnabb-La Roche Ag | N-(3-azabicyclo[3.2.1]octan-8-yl)-8-(4-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[l,5-a]pyridin-2-amine derivatives as gamma-secretase modulators for treating alzheimer's disease |
CN108137579B (zh) * | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
EP3475279B1 (en) * | 2016-06-27 | 2021-07-14 | F. Hoffmann-La Roche AG | Triazolopyridines as gamma-secretase modulators |
CN109641912B (zh) * | 2016-11-01 | 2021-10-29 | 豪夫迈·罗氏有限公司 | 二环杂芳基衍生物 |
US11319314B2 (en) * | 2016-11-08 | 2022-05-03 | Hoffmann-La Roche Inc. | Phenoxytriazoles |
AU2017376109A1 (en) | 2016-12-16 | 2019-07-11 | Pipeline Therapeutics, Inc. | Methods of treating cochlear synaptopathy |
-
2019
- 2019-12-11 MA MA054447A patent/MA54447A/fr unknown
- 2019-12-11 JP JP2021533563A patent/JP2022513466A/ja active Pending
- 2019-12-11 SG SG11202103340PA patent/SG11202103340PA/en unknown
- 2019-12-11 CN CN202311792520.6A patent/CN117946116A/zh active Pending
- 2019-12-11 EP EP19824250.5A patent/EP3894411A1/en active Pending
- 2019-12-11 CN CN201980076253.8A patent/CN113179641B/zh active Active
- 2019-12-11 IL IL310081A patent/IL310081A/en unknown
- 2019-12-11 KR KR1020217017774A patent/KR20210102900A/ko unknown
- 2019-12-11 BR BR112021009443-1A patent/BR112021009443A2/pt unknown
- 2019-12-11 CA CA3117870A patent/CA3117870A1/en active Pending
- 2019-12-11 AU AU2019395774A patent/AU2019395774A1/en active Pending
- 2019-12-11 MX MX2021006761A patent/MX2021006761A/es unknown
- 2019-12-11 PE PE2021000726A patent/PE20211776A1/es unknown
- 2019-12-11 IL IL283823A patent/IL283823B1/en unknown
- 2019-12-11 CR CR20210305A patent/CR20210305A/es unknown
- 2019-12-11 US US17/413,413 patent/US20220056036A1/en active Pending
- 2019-12-11 WO PCT/EP2019/084538 patent/WO2020120521A1/en unknown
- 2019-12-12 AR ARP190103631A patent/AR116906A1/es unknown
- 2019-12-12 TW TW108145480A patent/TWI831892B/zh active
-
2021
- 2021-05-24 CO CONC2021/0006837A patent/CO2021006837A2/es unknown
- 2021-06-11 CL CL2021001547A patent/CL2021001547A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP3894411A1 (en) | 2021-10-20 |
AR116906A1 (es) | 2021-06-23 |
MA54447A (fr) | 2022-03-23 |
CL2021001547A1 (es) | 2021-12-24 |
IL283823B1 (en) | 2024-03-01 |
JP2022513466A (ja) | 2022-02-08 |
SG11202103340PA (en) | 2021-04-29 |
CA3117870A1 (en) | 2020-06-18 |
PE20211776A1 (es) | 2021-09-08 |
IL283823A (en) | 2021-07-29 |
KR20210102900A (ko) | 2021-08-20 |
WO2020120521A1 (en) | 2020-06-18 |
CN113179641A (zh) | 2021-07-27 |
CO2021006837A2 (es) | 2021-06-10 |
IL310081A (en) | 2024-03-01 |
MX2021006761A (es) | 2021-07-15 |
BR112021009443A2 (pt) | 2021-08-17 |
AU2019395774A1 (en) | 2021-04-08 |
TWI831892B (zh) | 2024-02-11 |
US20220056036A1 (en) | 2022-02-24 |
CN117946116A (zh) | 2024-04-30 |
TW202039499A (zh) | 2020-11-01 |
CN113179641B (zh) | 2024-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ592685A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
NZ612041A (en) | Compounds and their use as bace inhibitors | |
RU2013138733A (ru) | Конденсированные производные аминодигидротиазина | |
PH12015501878A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative | |
NZ601150A (en) | Novel substituted bicyclic triazole derivatives as gamma secretase modulators | |
EA023824B1 (ru) | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) | |
NZ605486A (en) | Spiro-cyclic amine derivatives as s1p modulators | |
NZ629453A (en) | Thiazole derivatives as alpha 7 nachr modulators | |
MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
MX343788B (es) | Derivados de heteroarilo como moduladores de nachr alfa 7. | |
WO2006026204A3 (en) | Novel gamma-lactams as beta-secretase inhibitors | |
MX2021011118A (es) | Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. | |
SI2875011T1 (en) | 5-HT3 receptor antagonists | |
MX344696B (es) | Derivados de pirrol como moduladores de los receptores de acetilcolina nicotinicos para su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer y la enfermedad de parkinson. | |
MX2022006470A (es) | Tiromimeticos novedosos. | |
MX2012003720A (es) | N-((1r,2s,5r)-5-(tert-butilamino)-2-((s)-3-(7-tert-butilpirazolo[ 1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)a cetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos. | |
WO2021012049A8 (en) | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors | |
EA202190323A1 (ru) | ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk | |
SA518400501B1 (ar) | مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل) | |
PE20212113A1 (es) | Inhibidores de moleculas pequenas de la familia de quinasas jak | |
PH12019501968A1 (en) | PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | |
PH12020550761A1 (en) | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | |
MX2021013576A (es) | Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo. | |
CR20210305A (es) | Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b] [1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa paar el tratamiento de la enfermedad de alzheimer |